Skip to main content
. Author manuscript; available in PMC: 2018 May 31.
Published in final edited form as: Vaccine. 2017 May 5;35(24):3171–3177. doi: 10.1016/j.vaccine.2017.04.077

Figure 2.

Figure 2

Co-localization of 7DW8-5 and AdPyCS in dLN-resident DCs facilitates activation and recruitment of the DCs and enhances T-cell immunogenicity and efficacy of AdPyCS vaccine. (A–C) BALB/c mice (n=4/group) were immunized i.m. with 5 × 109 v.p. of Ad(PyCS-GFP) alone or together with 1 μg of each glycolipid. Sixteen hr later, lymphocytes were isolated from PLNs, and the (A) the percentage of GFP+ DC, (B) MHC II expression and (C) CD86 expression were determined by FACS. Data for individual mice are shown; line represents mean. (D) MHC I-Kd, CD11c-Kd and huCD68-Kd transgenic mice (n=4/group) were immunized i.m. with 5 × 109 v.p. of AdPyCS alone or together with 1 μg each glycolipid. Twelve days later, splenocytes were harvested, and the PyCS-specific CD8+ T-cell response was determined by an IFN-γ ELIspot assay. Mean ± S.D is shown.